Antenatal Screening Services

Antenatal screening

We offer ABO and RhD blood grouping and red cell antibody screen for antenatal samples. We provide RhD negative cards in compliance with BCSH guidelines as well as antibody cards.

Hard copy reminders will be sent to customers where 28 week screening samples have not been received.

Please note: if the red cell antibody-screening test is positive, we will reflex test the sample onto the reference sample pathway and charge only the price of the reference investigation.

Turnaround time

The report will be available within 2 working days of receipt by NHSBT. Our extended working day ensures prompt sample processing and testing.

Reporting

This is via Sp-ICE and a paper copy sent to the laboratory by agreement.

 

The Microbiological Screening programme

The purpose of microbiological screening in pregnancy is:

• To identify infection which could be harmful to the fetus or baby

• Reduce the risk to the baby

• Support control with appropriate management

Microbiological screening tests for all infections currently included in the programme:

  • Treponema pallidum (syphilis) antibody

  • Hepatitis B surface antigen

  • HIV 1&2 antibodies

Discretionary testing

Hepatitis C antigen testing can be performed on request.  

Testing is fully automated and benefits from the scale and security of our donation testing facilities.

Information leaflet

For information, please contact:

Erika Rutherford
RCI Business Development Manager
Mobile: 0780 890 6398
Email: erika.rutherford@nhsbt.nhs.uk

Ian Skidmore
RCI Reference Service Manager
Telephone: 0121 278 4125
Email: ian.skidmore@nhsbt.nhs.uk 

Fetal RHD Screening Service

We offer a fetal RHD screening service to prevent unnecessary administration of anti-D prophylaxis. The test predicts fetal RhD status with high accuracy from a sample of maternal blood and will improve care for RhD-negative women in England by reducing the need to administer a blood product to healthy pregnant women.

The NICE recommendation for high-throughput non invasive prenatal testing (NIPT) for fetal RHD has been published on their website as a cost-effective option to guide antenatal prophylaxis with anti-D immunoglobulin (anti-D Ig).

Please read our brochure for information about the fetal RHD screening test. 

Population distribution

The prevalence of RhD-negative women in a Caucasian population is 15%, of which 38% to 40% will have RhD-negative babies. These figures will differ depending on the ethnic diversity of the local population, which may affect projected cost savings for implementation of the test.

The cost of the test is offset by:

  • Reduction in administration of anti-D Ig at 28 weeks

  • Reduction in administration of anti-D Ig for potentially sensitising events in pregnancy

  • Decrease in associated requests for feto-maternal haemorrhage estimation

Sample acquisition

The service is tailored to the needs of local maternity services. Samples can be taken from 11 weeks gestation at a routine antenatal clinic appointment.

Logistics

NHSBT routine transport from local hospitals. The sample has to reach IBGRL within 7 days of the date taken.

Turnaround time

14 days from receipt at IBGRL.

Reporting

This is via Sp-ICE only.

Please note: this service is only available to NHS Trusts who have signed a contract for this service with NHSBT. This is not a diagnostic test for fetal RhD status for women who have made anti-D. See information for the management of pregnant women with alloantibodies.

Documentation

  • Fetal RHD screening service user guide (INF1259)

  • Guidance for completion of FRM5197 fetal RHD screening referral form (INF1340)

  • Fetal RHD screening referral for (FRM5197)
  • Filton IBGRL fetal genotype screen box labels 

Information for patients

D negative Mother's blood test to check her unborn baby's blood group (INF1263). This leaflet explains why it is important to have a blood test to check the baby’s blood group, so that only those who need it, receive anti-D injections, and describes what is haemolytic disease of the fetus and newborn, previously called Rhesus disease.

For information please contact:

Erika Rutherford
RCI Business Development Manager
Mobile: 0780 890 6398
Email: erika.rutherford@nhsbt.nhs.uk

Kirstin Finning
IBGRL Head of Molecular Diagnostics
Mobile: 0747 114 7733
Email: 
kirstin.finning@nhsbt.nhs.uk